Nghiên cứu tỷ lệ đáp ứng và kháng MTX ở bệnh nhân u nguyên bào nuôi tại Bệnh viện Phụ sản Trung ương

Objective: Describe clinical characteristics and treatment response rate of MTX regimen of 341 patients with gestational trophoblastic tumors. Study Design: A total of 341 patients with gestational trophoblastic tumors (choriocarcinoma, Placental-site trophoblastic tumor and invasive mole) received treatment at the National hospital of obstetrics and gynecology from 01/01/2010 to 31/12/2011. The 341 patients, 322 (94.5 percent) were treated initially with single-agent methotrexate 0.4 mg/kg intravenously daily for 5 days per treatment course repeated every 14 days. Results: 1. Patients in reproductive age accounted for most (68.3 percent). Patients do not have enough children at high percentage (62.2 percent), gestational trophoblastic tumors majority appear after hydatidiform mole (78.6 percent), the patient was diagnosed with 4 months accounted for most (78 percent). 195 patients with metastatic is (57.2 percent). Group patients with betahCG level 103 occupies the most (32.3 percent). Histopathological results showed Invasive mole ratio accounts for most (43.5 percent).2. Of the 322 patients initially treated with methotrexate, resistance developed in 79 (24.5 percent).